By Turna Ray
The latest diagnostic in Abbott's portfolio to receive a thumbs up from the US Food and Drug Administration is a genetic test aimed at predicting the prognosis of acute myeloid leukemia patients.
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
In Science this week: genetic target for urothelial bladder cancer treatment, and more.
At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.
A Karmagenes researcher has lost his position after reportedly admitting to data fabrication, according to Retraction Watch.
Two neuroscientists write in Nature News that solving the "reproducibility crisis" in science may require changing the requirements for publication.